algorithm

Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia

by

Research col­lab­o­ra­tion will test nov­el algorithm’s effec­tive­ness on Geisinger data (press release):

Geisinger and Eisai Inc. today announced a col­lab­o­ra­tive effort to study the poten­tial effec­tive­ness of an arti­fi­cial intel­li­gence (AI) tool in the detec­tion of cog­ni­tive impair­ment that could iden­ti­fy demen­tias, includ­ing Alzheimer’s dis­ease (AD). If effec­tive, the AI tool could poten­tial­ly be devel­oped to sup­port the ear­ly detec­tion and stag­ing of cog­ni­tive impair­ment and demen­tia, lead­ing to appro­pri­ate addi­tion­al test­ing for the clin­i­cal, bio­log­i­cal diag­no­sis and treat­ment of demen­tias such as AD. [Read more…] about Geisinger and Eisai to test real-world valid­i­ty of AI-pow­ered Pas­sive Dig­i­tal Mark­er (PDM) in detect­ing ear­ly cog­ni­tive impair­ment and dementia

Machine-learning study finds EEG brain signatures that predict response to antidepressant treatments

by

–

Brain-wave pat­tern can iden­ti­fy peo­ple like­ly to respond to anti­de­pres­sant, study finds (Stan­ford Med­i­cine press release):

“A new method of inter­pret­ing brain activ­i­ty could poten­tial­ly be used in clin­ics to help deter­mine the best treat­ment options for depres­sion, accord­ing to a study led by researchers at the Stan­ford School of Medicine.

Stan­ford researchers and their col­lab­o­ra­tors used elec­troen­cephalog­ra­phy, a tool for mon­i­tor­ing elec­tri­cal activ­i­ty in the brain, and an algo­rithm to iden­ti­fy a brain-wave sig­na­ture in [Read more…] about Machine-learn­ing study finds EEG brain sig­na­tures that pre­dict response to anti­de­pres­sant treatments

The FDA creates new Digital Health unit to reimagine regulatory paths in the age of scalable, AI-enhanced innovation

by

—

Med­i­cine Is Going Dig­i­tal. The FDA Is Rac­ing to Catch Up (Wired):

“WHEN BAKUL PATEL start­ed as a pol­i­cy advi­sor in the US Food and Drug Admin­is­tra­tion in 2008, he could pret­ty much pin­point when a prod­uct was going to land in front of the review­ers in his divi­sion. Back when med­ical devices were heavy on the hardware—your pace­mak­ers and your IUDs—it would take man­u­fac­tur­ers years to get them ready for reg­u­la­to­ry approval. FDA review­ers could keep up pret­ty well [Read more…] about The FDA cre­ates new Dig­i­tal Health unit to reimag­ine reg­u­la­to­ry paths in the age of scal­able, AI-enhanced innovation